Search
Close this search box.
Search
Close this search box.

New Study Finds NuvaRing and YYO Increase Risk of VTE

By Rheingold Giuffra Ruffo & Plotkin LLP

A new study recently published by the FDA ahead of a meeting of the Reproductive Health Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee on December 8th showed that NuvaRing (Etonogestrel) and Yaz, Yasmin, and Ocella(Drospirenone) increase the risk of certain users having a venous thrombotic event such as a deep vein thrombosis (DVT) which can lead to a pulmonary embolism (PE).

The study notes it is the first one to show an increase in the likelihood of a VTE in users of Etonogestrel and that futher studies must be done to replicate these results before they can be verified. The findings with regards to drospirenone have been demonstrated in other studies and come just ahead of a meeting to discuss the safety of drospirenone and their risk of blood clots.

If you have had a VTE, DVT, or PE after using Yaz, Yasmin, Ocella or NuvaRing contact the attorneys at Rheingold, Giuffra, Ruffo & Plotkin LLP for a free consultation with an experienced product liability lawyer.

Categories
Related Posts

Paragard Bellwether Trial Update

The Paragard Multidistrict Litigation is moving forward after US District Court Judge issued the latest scheduling order concerning deadlines for discovery, including disclosure of experts

View Article